Tin tức & Cập nhật
Xem bài viết Dược
Xem
Novel cancer vaccine plus pembrolizumab prolongs PFS in advanced melanoma
An investigational, immune-modulatory cancer vaccine, IO102-IO103, when combined with pembrolizumab results in sustained progression-free survival (PFS) compared with pembrolizumab alone in patients with advanced melanoma, reports a study.
Novel cancer vaccine plus pembrolizumab prolongs PFS in advanced melanoma
11 Jul 2026
1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL
The final results of the CLL14 trial validate the long-term efficacy of 1-year fixed-duration venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia (CLL) and co-existing conditions.
1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL
10 Jul 2026
GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer
Updates from the GARNET trial underpin dostarlimab monotherapy as a meaningful treatment option for women with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) advanced/recurrent endometrial cancer (A/R EC) who progressed after prior platinum therapy.
GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer
09 Jul 2026
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
A novel oral formulation of paclitaxel, DHP107, is noninferior to weekly intravenous (IV) paclitaxel in the treatment of HER2-negative recurrent or metastatic breast cancer, as shown by the results of the phase III OPTIMAL study.